A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs

NCT06232564 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumors

Interventions

COMBINATION_PRODUCT: Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy

Sponsor

Imperial College London